Specifically, FGF2 is the main member of the FGF family implicated in cancer development and drug resistance (85), and PDGFD and its receptor (PDGFRB) have been recently defined as key drivers of tumor progression since a PDGFRB downregulation impairs immediately GBM progression (A.C.V.-B. Here, PDGFRB is linked to glioblastoma.